Comparison between Anthem Biosciences IPO and Sri Lotus Developers IPO.
Anthem Biosciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Sri Lotus Developers IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Anthem Biosciences IPO is up to ₹3,395.00 Cr whereas the issue size of the Sri Lotus Developers IPO is up to ₹792.00 Cr. The final issue price of Anthem Biosciences IPO is ₹570.00 per share and of Sri Lotus Developers IPO is ₹150.00 per share.
| Anthem Biosciences IPO | Sri Lotus Developers IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹1 per share |
| Issue Price (Lower) | ₹540.00 per share | ₹140.00 per share |
| Issue Price (Upper) | ₹570.00 per share | ₹150.00 per share |
| Issue Price (Final) | ₹570.00 per share | ₹150.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ₹50.00 per share | ₹14.00 per share |
| Market Lot Size | 26 shares | 100 shares |
| Fresh Issue Size | 0 shares | 5,28,13,724 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹792.00 Cr |
| OFS Issue Size | 5,95,75,319 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹3,395.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 5,95,75,319 shares | 5,28,13,724 shares |
| Issue Size Total (Amount) | up to ₹3,395.00 Cr | up to ₹792.00 Cr |
Anthem Biosciences IPO opens on Jul 14, 2025, while Sri Lotus Developers IPO opens on Jul 30, 2025. The closing date of Anthem Biosciences IPO and Sri Lotus Developers IPO is Jul 16, 2025, and Aug 01, 2025, respectively.
| Anthem Biosciences IPO | Sri Lotus Developers IPO | |
|---|---|---|
| Anchor Bid Date | Jul 11, 2025 | Jul 29, 2025 |
| Issue Open | Jul 14, 2025 | Jul 30, 2025 |
| Issue Close | Jul 16, 2025 | Aug 01, 2025 |
| Basis Of Allotment (Tentative) | Jul 17, 2025 | Aug 04, 2025 |
| Initiation of Refunds (Tentative) | Jul 18, 2025 | Aug 05, 2025 |
| Credit of Share (Tentative) | Jul 18, 2025 | Aug 05, 2025 |
| Listing date (Tentative) | Jul 21, 2025 | Aug 06, 2025 |
| Anchor Lockin End date 1 | Aug 15, 2025 | Sep 02, 2025 |
| Anchor Lockin End date 2 | Oct 14, 2025 | Nov 01, 2025 |
Anthem Biosciences IPO P/E ratio is 70.62, as compared to Sri Lotus Developers IPO P/E ratio of 28.69.
| Anthem Biosciences IPO | Sri Lotus Developers IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Anthem Biosciences Ltd.'s revenue increased by 30% and profit after tax (PAT) rose by 23% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Sri Lotus Developers & Realty Ltd.'s revenue increased by 22% and profit after tax (PAT) rose by 91% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 76.87 | 91.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 74.68 | 81.86 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 70.62 | 28.69 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹31867.39 Cr. | ₹7330.65 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 20.82% | 24.39% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 26.88% | 27.22% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.05 | 0.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹8.07 | ₹5.23 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 20.82% | 24.39% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Anthem Biosciences IPO Retail Individual Investors (RII) are offered 2,07,95,834 shares while in Sri Lotus Developers IPO retail investors are offered 2,07,95,834 shares. Qualified Institutional Buyers (QIB) are offered 1,18,83,333 shares in Anthem Biosciences IPO and 1,05,33,333 shares in Sri Lotus Developers IPO.
| Anthem Biosciences IPO | Sri Lotus Developers IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,78,24,999 shares | 1,57,99,999 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 1,18,83,333 shares | 1,05,33,333 shares |
| NII | 89,12,500 shares | 79,00,000 shares |
| RII | 2,07,95,834 shares | 1,84,33,334 shares |
| Employee | 1,58,653 shares | 1,47,058 shares |
| Others | ||
| Total | 5,95,75,319 shares | 5,28,13,724 shares |
Anthem Biosciences IPO subscribed 67.42x in total, whereas Sri Lotus Developers IPO subscribed 74.10x.
| Anthem Biosciences IPO | Sri Lotus Developers IPO | |
|---|---|---|
| QIB (times) | 192.80x | 175.61x |
| NII (times) | 44.70x | 61.82x |
| Big NII (times) | 51.66x | 59.13x |
| Small NII (times) | 30.80x | 67.22x |
| RII (times) | 5.98x | 21.77x |
| Employee (times) | 6.99x | 21.37x |
| Other (times) | ||
| Total (times) | 67.42x | 74.10x |
